NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03950154,Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT03950154,,RECRUITING,"This study evaluates the effect and safty of PD-1 monoclonal antibody-activated autologous peripheral blood lymphocyte (PD1-T) combined with XELOX and bevacizumab in the first-line treatment of recurrent and metastatic colorectal cancer. Half of participants receive PD1-T combined with XELOX and bevacizumab, while the other half will receive XELOX and bevacizumab.",NO,Colorectal Cancer,DRUG: Bevacizumab Injection [Avastin]|DRUG: Oxaliplatin|DRUG: Capecitabine|BIOLOGICAL: PD1-T cells,"Progression-free survival, PFS will be calculated from initiation of treat- ment until first progression, and patients alive in stable state will be censored at the time of last contact., 3 years",,,Tianjin Medical University Cancer Institute and Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE3,198,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,B2019-023-01,2019-06-01,2023-08-01,2023-08-01,2019-05-15,,2023-08-01,"Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, 300060, China",
